Acta Neuropathologica

, Volume 63, Issue 4, pp 334–343 | Cite as

Neuropathologic study on chronic neurotoxicity of 5-fluorouracil and its masked compounds in dogs

  • R. Okeda
  • T. Karakama
  • S. Kimura
  • S. Toizumi
  • T. Mitsushima
  • Y. Yokoyama
Original Works


5-Fluorouracil (FU) and its masked compounds tegafur (FT) and carmofur (HCFU) were administered orally to Beagle dogs daily for 6 months, and their chronic neurotoxic effects were examined morphologically.

In ten dogs that survived the 6-month treatment large vacuoles produced by splitting of the intraperiod line of myelin were observed in the fornix in the wall of the third ventricle. In severely affected dogs large vacuoles developed in the medial preoptic area, medial portion of the internal capsule, the area around the subthalamic nucleus and the mammillo-thalamic tract. Axons of myelinated fibers affected by vacuolation were generally well maintained, and destruction of myelin was not detected. Though proliferation of glia cells or abnormality of oligodendroglia was not detected, a lipid deposit covered by a single layer membrane was observed in the cell bodies and processes of astrocytes. No abnormality was detected by electron microscopy in the cerebrum, inferior colliculus, cerebellum, or pons. Of eight dogs that died during the treatment period, large vacuoles were observed in the fornix in the wall of the third ventricle of four dogs treated for more than 1 month, and large vacuoles were present in the inferior colliculus in two dogs of the FT group in the above four dogs. In the HCFU group, the interruption of treatment for 6months resulted in alleviation or disappearance of the vacuolar lesions. The above findings suggest that the neurotoxicity of FU and its masked compounds FT and HCFU in long-term treatment produces changes morphologically identical with one another in respect to the site of their manifestation and nature of lesion, that their common degraded product α-fluoro-β-alanine (FBAL) plays a crucial role in their neurotoxic actions, and that vacuolar lesions, to which myelin was more vulnerable than neurons, can develop where the toxic substance readily deposits and accumulates.

Key words

5-Fluorouracil Tegafur Carmofur Neurotoxicity Intralamellar splitting 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bergevin PR, Patwardhan VC, Weissman J, Lee SM (1975) Neurotoxicity of 5-fluorouracil. Lancet I:410Google Scholar
  2. Bixenman WW, Nicholls JVV, Warwick OH (1977) Oculomotor disturbances associated with 5-fluorouracil chemotherapy. Am J Ophthalmol 83:789–793Google Scholar
  3. Boileau G, Piro AJ, Lahiri SR, Hall TC (1971) Cerebellar ataxia during 5-fluorouracil (NSC-19893) therapy. Cancer Chemother Rep 55:595–598Google Scholar
  4. Bourke RS, Charles RW, Chheda G, Tower DB (1973) Kinetics of entry and distribution of 5-fluorouracil in cerebrospinal fluid and brain following intravenous injection in a primate. Cancer Res 33:1735–1746Google Scholar
  5. Chadwick M, Rogers WI (1972) The physiological disposition of 5-fluorouracil in mice bearing solid L1210 lymphocytic leukemia. Cancer Res 32:1045–1056Google Scholar
  6. Gottlieb JA, Luce JK (1971) Cerebellar ataxia with weekly 5-fluorrouracil administration. Lancet 1:138–139Google Scholar
  7. Greco CM, Powell HC, Garrett RS, Lampert PW (1980) Cycloleucine encephalopathy. Neuropathol Appl Neurol 6:349–360Google Scholar
  8. Greenwald ES (1976) Organic mental changes with fluorouracil therapy. JAMA 235:248–249Google Scholar
  9. Henni Zen-ichi, Nishina T, Yoshihara K, Ishi M, Tanaka Y, Kitano T (1980) General pharmacological studies on 1-hexylcarbamoyl-5-fluorouracil (HCFU), a new antitumor agent. Oyo Yakuri 19:369–382Google Scholar
  10. Hirano A, Dembitzer HM (1967) A structural analysis of the myelin sheath in the central nervous system. J Cell Biol 34:555–567Google Scholar
  11. Hirano A, Zimmerman HM, Levine S (1968) Intramyelinic and extracellular spaces in thriethyltin intoxication. J Neuropathol Exp Neurol 27:571–580Google Scholar
  12. Hirano A, Dembitzer HM, Zimmerman HM (1969) The distribution of peroxidase in the triethyltin-intoxicated rat brain. J Neuropathol Exp Neurol 28:507–511Google Scholar
  13. Horton J, Olson KB, Sullivan J, Reilly C, Shnider B, The Eastern Cooperative Oncology Group (1970) 5-Fluorouracil in cancer: An improved regimen. Ann Int Med 73:897–900Google Scholar
  14. Ishimura K, Toizumi S, Neda K, Inoue H, Sato H, Sato K, Niyokawa H (1979) toxicological study on 1-hexylcarbamoyl-5-fluorouracil (HCFU). 2. Subacute and chronic toxicity studies in dogs. Pharmacometrics 17:597–615Google Scholar
  15. Kimbrough RD (1973) Review of recent evidence of toxic effects of hexachlorophene. Pediatrics 51:391–394Google Scholar
  16. Kobari T, Tan K, Kumakura M, Watanabe S, Shirakawa I, Kobayashi H, Ujiie A, Miyama Y, Namekawa H, Yamamoto H (1978) Metabolic fate of 1-hexylcarbamoyl-5-fluorouracil in rats. Xenobiotical 8:547–556Google Scholar
  17. Kobari T, Iguro Y, Ujiie A, Namekawa H (1981) Metabolism of 1-hexylcarbamoyl-5-fluorouracil (HCFU), a new antitumour agent, in rats, rabbits, and dogs. Xenobiotica 11:57–62Google Scholar
  18. Koenig H (1969) Acute axonal dystrophy caused by fluorocitrate: The role of mitochondrial swelling. Science 164:310–312Google Scholar
  19. Koenig H, Patel A (1969) Biochemical basis of the acute cerebellar syndrome in 5-fluorouracil chemotherapy. Trans Am Neurol Assoc 94:290–292Google Scholar
  20. Koenig H, Pattel A (1970) Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate. Arch Neurol 23:155–160Google Scholar
  21. Lynch HT, Droszcz CP, Albano WA, Lynch JF (1981) “Organic brain syndrome” secondary to 5-fluorouracil toxicity. Dis Colon Rectum 24:130–131Google Scholar
  22. MacDonell LA, Potter PE, Leslie RA (1978) Localized changes in blood-brain barrier permeability following the administration of antineoplastic drugs. Cancer Res 38:2930–2934Google Scholar
  23. Moertel CG, Reitemeier RJ, Bolton CF, Shorter RG (1964) Cerebellar ataxia associated with fluorinated pyrimidine therapy. Cancer Chemother Rep 41:15–18Google Scholar
  24. Mukherjee KL, Heidelberger C (1960) Studies on fluorinated pyrimidines. IX. The degradation of 5-fluorouracil-6-C14. J Biol Chem 235:433–437Google Scholar
  25. Mukherjee KL, Boohar J, Wentland D, Ansfield FJ, Heidelberger C (1963) Studies on fluorinated pyrimidines. XVI. Metabolism of 5-fluorouracil-2-C14 and 5-fluoro-2′-deoxyuridine-2-C14 in cancer patients. Cancer Res 23:49–66Google Scholar
  26. Mullick FG (1973) Hexachlorophene toxicity—human experience at the Armed Forces Institute of Pathology. Pediatrics 51:395–399Google Scholar
  27. Oishi T, Shiraki H, Mineura K, Takahira H (1973) The study on metabolic fate of 5-fluorouracil-6-14C after percutaneous administration (in Japanese). Yakugaku Zasshi 93:749–755Google Scholar
  28. Palay SL, Chan-Palay V (1974) Cerebellar cortex: cytology and organization. Springer, Berlin Heidelberg New YorkGoogle Scholar
  29. Pattison FLM, Peters RA (1966) Monofluoro aliphatic compounds. Handbool of experimental pharmacology, vol 20, part 1. Springer, Berlin Heidelberg New York, pp 387–458Google Scholar
  30. Riehl J-L, Brown WJ (1964) Acute cerebellar syndrome secondary to 5-fluorouracil therapy. Neurology 14:961–967Google Scholar
  31. Scriver CR, Pueschel S, Davies E (1966) Hyper-β-alaninemia associated with β-aminoaciduria and γ-aminobutyric acid uria, somnolence and seizures. New Engl J Med 274:635–643Google Scholar
  32. Sueyoshi K, Uozumi A, Majima H (1980) Concentration of 1-hexylcarbamoyl-5-fluorouracil (HCFU) fraction and 5-fluorouracil in central nervous system after HCFU oral administration (in Japanese). Gan to kagakuryoho 7:870–874Google Scholar
  33. Tripier MF, Berard M, Toga M, Martin-Bouyer G, Le Breton R, Garat J (1981) Hexachlorophene and the central nervous system. Toxic effects in mice and baboons. Acta Neuropathol (Berl) 53:65–74Google Scholar
  34. Towfighi J, Gonatas NK, McCree L (1973) Hexachlorophene neuropathy in rats. Lab Invest 29:428–436Google Scholar
  35. Weiss HD, Walker MD, Wiernik PH (1974) Neurotoxicity of commonly used antineoplastic agents (first of two parts). New Engl J Med 291:75–81Google Scholar
  36. Yabuuchi Y, Osame Y, Takikawa K, Fujii T, Ozaki T, Harima, K (1971) General pharmacological studies of N1-(2-tetrahydrofuryl)-5-fluorouracil, FT-207, a new anticancerous agent. (in Japanese with english summary Pharmacometrics 5:569–584Google Scholar
  37. Yamashita K, Fukunaga Y, Maruden A, Takenouchi T, Morita K (1980) Subacute toxicity of UFT, a new anti-cancer agent orally administrated in dogs (in Japanese). Pharmacometrics 20:973–999Google Scholar

Copyright information

© Springer-Verlag 1984

Authors and Affiliations

  • R. Okeda
    • 1
  • T. Karakama
    • 2
  • S. Kimura
    • 2
  • S. Toizumi
    • 2
  • T. Mitsushima
    • 2
  • Y. Yokoyama
    • 2
  1. 1.Dept. of Pathology, Medical Research InstituteTokyo Medical and Dental UniversityBunkyo-ku, TokyoJapan
  2. 2.Institute of Biological ScienceMitsui Pharmaceuticals, Inc.Mobara-shi, Chiba-kenJapan

Personalised recommendations